teplizumab or placebo
Phase 1Terminated 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Aug 1, 2010 โ Feb 1, 2011
NCT ID
NCT01189422About teplizumab or placebo
teplizumab or placebo is a phase 1 stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01189422. Target conditions include Type 1 Diabetes Mellitus.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01189422 | Phase 1 | Terminated |
Competing Products
20 competing products in Type 1 Diabetes Mellitus